X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CIPLA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CIPLA DR. REDDYS LAB/
CIPLA
 
P/E (TTM) x 29.9 44.6 67.1% View Chart
P/BV x 2.9 3.8 76.7% View Chart
Dividend Yield % 0.9 0.3 274.4%  

Financials

 DR. REDDYS LAB   CIPLA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
CIPLA
Mar-17
DR. REDDYS LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs3,397622 546.2%   
Low Rs2,560458 558.6%   
Sales per share (Unadj.) Rs856.5181.9 471.0%  
Earnings per share (Unadj.) Rs78.012.9 605.7%  
Cash flow per share (Unadj.) Rs139.929.3 477.2%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.70.4 181.3%  
Book value per share (Unadj.) Rs739.8155.7 475.2%  
Shares outstanding (eoy) m165.74804.51 20.6%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x3.53.0 117.1%   
Avg P/E ratio x38.242.0 91.0%  
P/CF ratio (eoy) x21.318.4 115.5%  
Price / Book Value ratio x4.03.5 116.0%  
Dividend payout %25.715.5 165.1%   
Avg Mkt Cap Rs m493,632434,516 113.6%   
No. of employees `00022.723.0 98.4%   
Total wages/salary Rs m31,06826,338 118.0%   
Avg. sales/employee Rs Th6,259.06,349.1 98.6%   
Avg. wages/employee Rs Th1,369.81,143.0 119.8%   
Avg. net profit/employee Rs Th569.7449.3 126.8%   
INCOME DATA
Net Sales Rs m141,961146,302 97.0%  
Other income Rs m1,7152,287 75.0%   
Total revenues Rs m143,676148,589 96.7%   
Gross profit Rs m24,72224,758 99.9%  
Depreciation Rs m10,26613,229 77.6%   
Interest Rs m6341,594 39.8%   
Profit before tax Rs m15,53712,222 127.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m349-70 -499.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9651,798 164.9%   
Profit after tax Rs m12,92110,354 124.8%  
Gross profit margin %17.416.9 102.9%  
Effective tax rate %19.114.7 129.7%   
Net profit margin %9.17.1 128.6%  
BALANCE SHEET DATA
Current assets Rs m96,83787,370 110.8%   
Current liabilities Rs m84,19933,081 254.5%   
Net working cap to sales %8.937.1 24.0%  
Current ratio x1.22.6 43.5%  
Inventory Days Days7387 84.4%  
Debtors Days Days9862 156.8%  
Net fixed assets Rs m102,552111,567 91.9%   
Share capital Rs m8291,609 51.5%   
"Free" reserves Rs m121,792123,645 98.5%   
Net worth Rs m122,621125,254 97.9%   
Long term debt Rs m5,44936,454 14.9%   
Total assets Rs m218,165209,532 104.1%  
Interest coverage x25.58.7 294.2%   
Debt to equity ratio x00.3 15.3%  
Sales to assets ratio x0.70.7 93.2%   
Return on assets %6.25.7 109.0%  
Return on equity %10.58.3 127.5%  
Return on capital %12.98.5 151.8%  
Exports to sales %54.634.2 159.6%   
Imports to sales %9.48.3 112.1%   
Exports (fob) Rs m77,52050,050 154.9%   
Imports (cif) Rs m13,27412,203 108.8%   
Fx inflow Rs m81,67051,066 159.9%   
Fx outflow Rs m26,35517,678 149.1%   
Net fx Rs m55,31533,388 165.7%   
CASH FLOW
From Operations Rs m21,44423,824 90.0%  
From Investments Rs m-18,404-13,127 140.2%  
From Financial Activity Rs m-3,692-13,239 27.9%  
Net Cashflow Rs m-1,144-2,478 46.2%  

Share Holding

Indian Promoters % 25.5 16.0 159.4%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.4 12.2 44.3%  
FIIs % 35.3 23.7 148.9%  
ADR/GDR % 18.5 1.1 1,681.8%  
Free float % 15.3 26.2 58.4%  
Shareholders   75,885 161,166 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS